ArticleScientific reports2026
Pueraria lobata extract mitigates diabetic nephropathy via NLRP3 inflammasome and Caspase-1 regulation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
To elucidate novel mechanisms underlying puerariae lobatae extract (EPL) therapeutic efficacy against diabetic nephropathy, with a focus on NLRP3 inflammasome regulation in streptozotocin (STZ)-induced renal pathology. 60 Wistar rats were randomly divided into five groups: a normal control (NC) group, a model (Model) group, an EPL (EPL) group, an NLRP3 activator group (NLRP3), and an NLRP3 activator + EPL group (NLRP3 + EPL), with 12 rats in each group. Diabetic kidney injury was induced in rats by intraperitoneal injection of streptozotocin (STZ). ELISA was used to measure serum creatinine (Scr), blood urea nitrogen (BUN), serum uric acid (SUA), 24-hour urinary albumin (UAlb), malondialdehyde (MDA) in renal tissue, superoxide dismutase (SOD), interleukin-1β (IL-1β), and IL-18. Histopathological changes in renal tissue were observed by hematoxylin and eosin (HE) staining. The content of reactive oxygen species (ROS) in renal tissue was detected by chemiluminescence. qRT-PCR was employed to detect the mRNA expression of NLRP3 and apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) in renal tissue. Western blot was used to assess the protein expression of NLRP3, ASC, and cysteine aspartic acid protease 1(caspase-1) in renal tissue. EPL intervention demonstrated: Significant body weight recovery (143.62 ± 6.18 g vs. DN 110.53 ± 5.69 g, P < 0.05); Renal functional restoration: 34.8% reduction in Scr (15.96 ± 2.31 vs. 35.19 ± 5.27 µmol/L), 49.7% decrease in BUN (9.16 ± 0.35 vs. 18.21 ± 0.85 mmol/L); Oxidative homeostasis improvement: 35.5% MDA reduction (2.38 ± 0.31 vs. 3.69 ± 0.42 nmol/mg), 56.8% ROS suppression (25.52 × 10⁴ vs. 59.08 × 10⁴/mg); Inflammasome downregulation: 62.3% decrease in NLRP3 mRNA, 58.1% ASC protein reduction, and 47.6% Caspase-1 activation inhibition. This study establishes that EPL ameliorates diabetic renal injury by suppressing NLRP3 inflammasome activation and Caspase-1-mediated signaling, providing mechanistic validation for EPL's therapeutic potential in metabolic nephropathy management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.